Literature DB >> 29610423

Neurotoxicity Associated with a High-Affinity GD2 CAR-Letter.

Robbie G Majzner1, Evan W Weber1, Rachel C Lynn1, Peng Xu1, Crystal L Mackall2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29610423     DOI： 10.1158/2326-6066.CIR-18-0089

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN： 2326-6066            Impact factor:   11.151


× No keyword cloud information.
  9 in total

Review 1.  Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy.

Authors:  Yanting Duan; Ruoqi Chen; Yanjie Huang; Xianhui Meng; Jiangqing Chen; Chan Liao; Yongmin Tang; Chun Zhou; Xiaofei Gao; Jie Sun
Journal:  Cell Mol Life Sci       Date:  2021-12-29       Impact factor: 9.261

2.  GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells.

Authors:  Christian M Seitz; Sarah Schroeder; Philipp Knopf; Ann-Christin Krahl; Jana Hau; Sabine Schleicher; Manuela Martella; Leticia Quintanilla-Martinez; Manfred Kneilling; Bernd Pichler; Peter Lang; Daniel Atar; Karin Schilbach; Rupert Handgretinger; Patrick Schlegel
Journal:  Oncoimmunology       Date:  2019-11-07       Impact factor: 8.110

3.  Exploiting Gangliosides for the Therapy of Ewing's Sarcoma and H3K27M-Mutant Diffuse Midline Glioma.

Authors:  Arthur Wingerter; Khalifa El Malki; Roger Sandhoff; Larissa Seidmann; Daniel-Christoph Wagner; Nadine Lehmann; Nadine Vewinger; Katrin B M Frauenknecht; Clemens J Sommer; Frank Traub; Thomas Kindler; Alexandra Russo; Henrike Otto; André Lollert; Gundula Staatz; Lea Roth; Claudia Paret; Jörg Faber
Journal:  Cancers (Basel)       Date:  2021-01-29       Impact factor: 6.639

4.  Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma.

Authors:  Babak Moghimi; Sakunthala Muthugounder; Samy Jambon; Rachelle Tibbetts; Long Hung; Hamid Bassiri; Michael D Hogarty; David M Barrett; Hiroyuki Shimada; Shahab Asgharzadeh
Journal:  Nat Commun       Date:  2021-01-21       Impact factor: 14.919

Review 5.  Harnessing the chemokine system to home CAR-T cells into solid tumors.

Authors:  Jade Foeng; Iain Comerford; Shaun R McColl
Journal:  Cell Rep Med       Date:  2022-02-28

6.  GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma.

Authors:  Nga T H Truong; Paris M Kollis; Kristyna Sedivakova; Tessa Gargett; Lisa M Ebert; Wenbo Yu; Erica C F Yeo; Nicole L Wittwer; Briony L Gliddon; Melinda N Tea; Rebecca Ormsby; Santosh Poonnoose; Jake Nowicki; Orazio Vittorio; David S Ziegler; Stuart M Pitson; Michael P Brown
Journal:  J Immunother Cancer       Date:  2022-09       Impact factor: 12.469

Review 7.  CAR T Cell Therapy for Neuroblastoma.

Authors:  Rebecca M Richards; Elena Sotillo; Robbie G Majzner
Journal:  Front Immunol       Date:  2018-10-16       Impact factor: 7.561

Review 8.  Carbohydrate Targets for CAR T Cells in Solid Childhood Cancers.

Authors:  Claudia Rossig; Sareetha Kailayangiri; Silke Jamitzky; Bianca Altvater
Journal:  Front Oncol       Date:  2018-11-12       Impact factor: 6.244

9.  Multimerization through Pegylation Improves Pharmacokinetic Properties of scFv Fragments of GD2-Specific Antibodies.

Authors:  Irina V Kholodenko; Daniel V Kalinovsky; Elena V Svirshchevskaya; Igor I Doronin; Maria V Konovalova; Alexey V Kibardin; Tatyana V Shamanskaya; Sergey S Larin; Sergey M Deyev; Roman V Kholodenko
Journal:  Molecules       Date:  2019-10-24       Impact factor: 4.411
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.